Platforms
STAR-TTM Cell Therapy Platform
The world’s first-in-class STAR-T technology integrates the strengths of direct CAR antigen recognition and native TCR signal transduction. It features high sensitivity, robust infiltration and resistance to T-cell exhaustion, with key findings published in Science and Cell family journals. This technology overcomes the efficacy bottleneck of conventional CAR-T in solid tumors and enables precise recognition of HLA-presented intracellular tumor neoantigens.
-
-
STAR structure resembles TCR, superior to CAR-T
See details about STAR-TSTAR-T platformSTAR-T platform
1. Potently eliminates tumors with low antigen expression: Antigen sensitivity is 10–100× higher than conventional CAR-T (Science Translational Medicine 2021; Cell Reports 2024)
2. Superior tissue infiltration: Deeply eliminates lesions in tissues, overcoming solid tumor hurdles; promising efficacy in organ-involved autoimmune diseases and solid tumors (Science Translational Medicine 2021)
3. Favorable clinical safety: Mild adverse reactions; rare mild-to-moderate CRS, no severe neurotoxicity (ASH 2020; American Journal of Hematology 2022)
Off-the-shelf STAR-T Platform
Off-the-shelf STAR-T Platform adopts the CRISPR-Cas9 gene-editing system and adeno-associated virus (AAV)-mediated site-specific integration strategy, which eliminates the risk of random genomic insertion and improves product safety. Meanwhile, it mitigates graft-versus-host disease (GVHD) and host-versus-graft reaction (HVGR) risks of universal products, enhances the cells’ resistance to immunosuppression and cytotoxicity, and features a clear drug development prospect.
-
-
Off-the-shelf STAR-T Technology Using One-Step Site-Specific Integration
See details about Off-the-shelf STAR-TSTAR-T platformOff-the-shelf STAR-T Platform
1. Precise site-specific integration: No random insertion-induced tumorigenesis; STAR replaces endogenous TCR at the TRAC constant region, with no severe GVHD in allogeneic infusion (Nature Medicine 2025)
2. Cost efficiency: Production cost is only 1/20 of autologous CAR-T; manufacturable, off-the-shelf, and scalable for industrialization
3. Full functional compensation: STAR completely restores TCR signaling, preserving T-cell proliferation, survival, and immune synapse function for sustained activity (Science Translational Medicine 2021)
In vivo STAR-T Platform
Bristar Immunotech's In vivo STAR-T Technology Platform is built on the core STAR-T structure and integrates proprietary technologies for in vivo delivery and in situ modification. It is a disruptive technology platform that accomplishes T cell engineering directly in vivo, eliminating the need for ex vivo cell preparation and patient leukapheresis.
-
-
In vivo STAR-T: Safer In vivo CAR-T
See details about In vivo STAR-TSTAR-T platformIn vivo STAR-T Platform
1. Precise T-cell targeting & specific activation: No damage to normal tissues or other immune cells, with an exceptional safety profile.
2. Efficiently transduces quiescent T cells: Preclinical data has been fully validated.
3. Clinical progress & broad indications: First-in-human clinical data will expected in Q4 2026; indications cover autoimmune diseases, CMV/EBV-associated diseases and malignancies.